Shuttle Pharmaceuticals (SHPH) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SHPH Shuttle Pharmaceuticals

Watchlist

0.795
+0.005+0.65%

Trading Dec 4 13:54 ET

2.91MMarket Cap-187P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma as UVA Cancer Center Doses Its First Patient
GlobeNewswireNov 26 09:00 ET
US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16 02:13 ET
Shuttle Pharmaceuticals Holdings, Inc. Advances Phase 2 Clinical Trial for Ropidoxuridine in Glioblastoma Treatment
Quiver QuantitativeNov 13 17:49 ET
Express News | Shuttle Pharmaceuticals Q3 EPS $(1.59) Down From $(0.91) YoY
BenzingaNov 13 17:10 ET
Shuttle Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
SECNov 13 17:06 ET · Announcements
Express News | Shuttle Pharma Provides Third Quarter 2024 Corporate Update
ReutersNov 13 17:00 ET

Comments

puan kalsom

Nov 8 05:37

$Shuttle Pharmaceuticals (SHPH.US)$

Stock_Drift

Oct 30 03:44

$Shuttle Pharmaceuticals (SHPH.US)$

Jaguar8

Oct 29 20:09

NEWS

$Shuttle Pharmaceuticals (SHPH.US)$
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Shuttle Pharmaceuticals Holdings(Nasdaq: SHPH) has announced pricing of a $4.5 million public offering priced at-the-market. The offering includes up to 2,950,820 shares of common stock (or pre-funded warrants) and warrants at $1.525 per share and accompanying warrant. The warrants, exercisable at $1.40 per share, will expire in f...